BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12014729)

  • 1. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
    Fargion S; Fracanzani AL; Rossini A; Borzio M; Riggio O; Belloni G; Bissoli F; Ceriani R; Ballarè M; Massari M; Trischitta C; Fiore P; Orlandi A; Morini L; Mattioli M; Oldani S; Cesana B; Fiorelli G
    Am J Gastroenterol; 2002 May; 97(5):1204-10. PubMed ID: 12014729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.
    Fontana RJ; Israel J; LeClair P; Banner BF; Tortorelli K; Grace N; Levine RA; Fiarman G; Thiim M; Tavill AS; Bonkovsky HL
    Hepatology; 2000 Mar; 31(3):730-6. PubMed ID: 10706565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.
    Tsai NC; Zuckerman E; Han SH; Goad K; Redeker AG; Fong TL
    Am J Gastroenterol; 1997 Oct; 92(10):1831-4. PubMed ID: 9382046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study].
    Ortiz V; Olaso V; López Viedma B; Córdoba J; Molina JM; Lainez B; Pastor M; Berenguer J
    Gastroenterol Hepatol; 1999 Mar; 22(3):122-6. PubMed ID: 10228321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.
    Di Bisceglie AM; Bonkovsky HL; Chopra S; Flamm S; Reddy RK; Grace N; Killenberg P; Hunt C; Tamburro C; Tavill AS; Ferguson R; Krawitt E; Banner B; Bacon BR
    Hepatology; 2000 Jul; 32(1):135-8. PubMed ID: 10869301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassemia major.
    Sievert W; Pianko S; Warner S; Bowden S; Simpson I; Bowden D; Locarnini S
    Am J Gastroenterol; 2002 Apr; 97(4):982-7. PubMed ID: 12003436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of serum immunoglobulin M to hepatitis C virus core in patients with chronic hepatitis C.
    Tran A; Yang G; Dreyfus G; Rouquié P; Durant J; Rampal A; Rampal P; Benzaken S
    Am J Gastroenterol; 1997 Oct; 92(10):1835-8. PubMed ID: 9382047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon retreatment in chronic hepatitis C: which patients to choose, and what schedule to use.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Torre F; Cipriani AG; Ponassi I; Varagona G; Grasso A; De Leo P; De Conca V; Mesiti S; Marenco G; Menardo G; Dodero M; Celle G
    Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):649-53. PubMed ID: 10418937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting interferon treatment response in patients with chronic hepatitis c: late viral clearance does not preclude a sustained response.
    Ebeling F; Lappalainen M; Vuoristo M; Nuutinen H; Leino R; Karvonen AL; Lehtola J; Julkunen R; Pohjanpelto P; Färkkilä M
    Am J Gastroenterol; 2001 Apr; 96(4):1237-42. PubMed ID: 11316176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.